We interviewed GraniteShares' CEO Will Rhind from New York, soon after they launched a suite of ETP's which allow you to invest in three different baskets of giant US tech stocks. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.10
Bid: 8.00
Ask: 8.20
Change: -0.15 (-1.82%)
Spread: 0.20 (2.50%)
Open: 8.25
High: 8.25
Low: 8.05
Yest. Close: 8.25
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

IN BRIEF: N4 Pharma Pretax Loss Widens; Aims To Maximise Nuvec Uses

Thu, 17th Sep 2020 14:36

N4 Pharma PLC - London-headquartered pharmaceutical company developing Nuvec vaccine and cancer treatment delivery system - Reports slightly widened GBP585,045 pretax loss for the six months ended June 30, compared to a GBP552,160 loss a year before. This is due to higher research and development costs of GBP213,869 compared to GBP117,694 a year prior. General and administration costs, however, are down at GBP371,197, compared to GBP432,879 prior year. Loss after tax narrows to GBP538,388 from GBP552,160 after GBP46,657 gain on taxation versus no gain the year before. Reports no revenue for either period as still developing Nuvec.

Chief Executive Nigel Theobald: "The arrival of the Covid-19 pandemic during the period has thrown up considerable challenges globally but also opportunities. Whilst continuing with our optimisation work of Nuvec as a delivery platform technology, the immediate need to address the threat of Covid-19 encouraged us to look at more specific, product driven, applications resulting in our proof of concept work with Nuvec loaded with the Coronavirus DNA plasmid. Our subsequent in vitro success was extremely pleasing but to maximise our chances of success in any full in vivo study we now need to incorporate the findings of our optimisation work. This is key as we look to further our work with the coronavirus plasmid in parallel to working with more generic DNA plasmids which may be more applicable in collaborations on multiple other vaccines. To that end, we are excited to be moving towards our most comprehensive in vivo study to date and are in the process of scoping the different aspects of the study.

"At the same time, we aim to maximise the potential uses of Nuvec as we continue to look at other applications including assessing its ability for use in the delivery of vaccines orally. We remain fully funded for the current work programmes, and I look forward to providing further updates in due course."

Current stock price: 6.37 pence

Year-to-date change: up sharply from 2.75p on December 31

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

17 Mar 21 16:31

N4 Pharma losses widen as it works on commercialising Nuvec

(Sharecast News) - Pre-revenue specialist pharmaceuticals company N4 Pharma reported an operating loss of £1.56m in its final results on Wednesday, widening from the £0.95m loss a year earlier.

24 Feb 21 12:34

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

24 Feb 21 10:25

N4 Pharma Loss Widens As Ramps Up R&D Investment At "Pivotal Time"

N4 Pharma Loss Widens As Ramps Up R&D Investment At "Pivotal Time"

24 Feb 21 10:03

N4 Pharma Shares Jump On European Patent Approval For Nuvec

N4 Pharma Shares Jump On European Patent Approval For Nuvec

11 Feb 21 11:53

AIM WINNERS & LOSERS: MediaZest Soars As Kicks Off 2021 With Deal Wins

AIM WINNERS & LOSERS: MediaZest Soars As Kicks Off 2021 With Deal Wins

11 Feb 21 11:21

IN BRIEF: N4 Pharma Raises GBP2 Million To Fund Development Work

IN BRIEF: N4 Pharma Raises GBP2 Million To Fund Development Work

9 Dec 20 14:04

UK WINNERS & LOSERS SUMMARY: Cineworld Falls On Warner Streaming Plans

UK WINNERS & LOSERS SUMMARY: Cineworld Falls On Warner Streaming Plans

4 Dec 20 10:33

N4 Pharma shares surge on latest from Nanomerics collaboration

(Sharecast News) - Specialist pharmaceuticals company N4 Pharma updated the market on its ongoing research collaboration agreement with Nanomerics on Thursday.

3 Dec 20 13:39

N4 Pharma Shares Soar As Cancer Drug Moves To Phase Two Of Programme

N4 Pharma Shares Soar As Cancer Drug Moves To Phase Two Of Programme

3 Dec 20 10:40

N4 Pharma working with Nanomerics on oncology programme

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has appointed Nanomerics to investigate the potential utility of its 'Nuvec' delivery system in cancer therapy.

9 Nov 20 14:22

N4 Pharma Plans Nuvec Oncology Treatment Study With UCL's Nanomerics

N4 Pharma Plans Nuvec Oncology Treatment Study With UCL's Nanomerics

9 Nov 20 14:20

UK TRADING UPDATE SUMMARY: Zotefoams Hails Record Third Quarter Sales

UK TRADING UPDATE SUMMARY: Zotefoams Hails Record Third Quarter Sales

5 Nov 20 18:07

IN BRIEF: N4 Pharma Pretax Loss Widens; Aims To Maximise Nuvec Uses

IN BRIEF: N4 Pharma Pretax Loss Widens; Aims To Maximise Nuvec Uses

17 Sep 20 14:36

N4 Pharma Plunges 40% As Covid-19 Antibody Delivery Study Disappoints

N4 Pharma Plunges 40% As Covid-19 Antibody Delivery Study Disappoints

14 Sep 20 10:52

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.